Company / Revenue
Intellia Therapeutics, Inc. Revenue History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Revenue
$67.7M
FY2025
5-year range
$36.3M / $67.7M
FY2021-FY2025
Trend
+16.9%
vs FY2024
Sector context
#152 of 156
Health Care
What the data says
Among 156 Health Care companies, Intellia Therapeutics, Inc. is in the bottom 3% for revenue. Revenue has fluctuated over the past 10 years, ranging from $16M in FY2018 to $68M in FY2025.
Based on SEC 10-K filings.
$68M in FY2025 with a 5-year CAGR of +3.1%.
Improved from $36M to $68M over the past 2 years.
Health Care sector context is included.
Revenue over time
Growth rates
- 3-Year CAGR
- +5.3%
- 5-Year CAGR
- +3.1%
- 10-Year CAGR
- -
Sector benchmark
Bottom 3% in Health CareTop 97% of 156This company $67.7M Sector average $19.0B
▼
-99.6% below sector average
Key checks
Key Insights
- 5-year CAGR of +3.1%, indicating consistent growth.
- In FY2025, revenue increased 16.9% year-over-year.
- Ranks #152 out of 156 companies in the Health Care sector.
- Lowest revenue in the period was in FY2018.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score -2.14 (distress zone, below 1.8 threshold)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | RevenueValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $67.7M | +16.9% |
| FY2024 | $57.9M | +59.6% |
| FY2023 | $36.3M | -37.5% |
| FY2022 | $58.0M | +34.5% |
| FY2021 | $43.1M | -25.7% |
| FY2020 | $58.0M | +122.1% |
| FY2019 | $26.1M | +58.5% |
| FY2018 | $16.5M | -36.9% |
| FY2017 | $26.1M | +58.5% |
| FY2016 | $16.5M | - |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026